Navigation Links
ViThera Novel Approach Using Probiotics to Deliver Elafin Shows Promise as a Future Inflammatory Bowel Disease (IBD) Treatment
Date:10/31/2012

CAMBRIDGE, Mass., Oct. 31, 2012 /PRNewswire/ -- ViThera Pharmaceuticals, Inc, a developer of novel therapeutics based on engineered probiotic bacteria, announced today the publication of breakthrough data validating its approach for the delivery of elafin in treating gastrointestinal inflammation. The results were published today by the journal Science Translational Medicine and show use of recombinant probiotic and non-pathogenic food-strain bacteria to deliver elafin, a protein designed to protect human mucosal tissue during inflammation. The publication by senior author Nathalie Vergnolle and ViThera co-founder Philippe Langella describes a series of preclinical experiments successfully validating elafin as a novel treatment approach with future applications for human inflammatory bowel disease (IBD).

ViThera's President, Johannes Fruehauf, commented, "We are excited about the recognition that this publication entails and we congratulate Nathalie and Philippe on this important achievement." ViThera has obtained worldwide exclusive rights to the technology and is developing it further towards validation in clinical trials in close collaboration with Dr. Vergnolle and Dr. Langella. ViThera's VT301 program, currently in preclinical development, focuses on restoring and maintaining the integrity of the gut epithelium in patients with IBD by delivering elafin. This treatment is designed to help patients with active disease achieve remission faster and patients in remission to avoid flare-ups. VT301 is expected to enter clinical trials in two years for patients with mild to moderate ulcerative colitis.

About ViThera Pharmaceuticals

ViThera is a startup biotechnology company based in Cambridge, Massachusetts. Its research combines innovative molecular biology with the benefits of probiotics to create therapeutics for a variety of chronic diseases, including inflammatory bowel diseases like Crohn's disease and ulcerative colitis. ViThera i
'/>"/>

SOURCE ViThera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
3. New magnetic-field-sensitive alloy could find use in novel micromechanical devices
4. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
5. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
6. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
7. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
8. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
9. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
10. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
11. Novel method to make nanomaterials discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... ... joint disease. , Equine cervical facet joint problems can be caused by ... and can cause impingement of nerve roots or of the spinal cord itself. ...
(Date:9/1/2015)... ... 2015 , ... Leading CEOs, CSOs, CMOs, and heads of ... prominent academics and key investors for Neuro Advance Boston, October 14, 2015 at ... , Neuro Advance Boston focuses on the latest developments and opportunities in neuroscience ...
(Date:9/1/2015)... Sept. 1, 2015   Medfusion, Inc., ... relationship between doctors and patients, today announced a ... N.C. -based venture capital firms.   ... association with Bull City Venture Partners and Hatteras ... Founder and Executive Chairman. "Both firms, experience working ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based ... researchers at the Keck Graduate Institute and its collaborators. The discovery has the ... were published online on August 27 by Scientific Reports, an open access research ...
Breaking Biology Technology:VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4
...   Synthetic Biologics, Inc. (NYSE Amex: SYN ), ... medicines for serious illnesses, announced today that to improve ... split the roles of Chairman and Chief Executive Officer, ... independent, non-executive Chairman of the Board. Mr. Kraws has ...
... 10, 2012   GeneLink, Inc. (OTC Bulletin ... biotech company, reports financial results for the fiscal year ended ... , The Company reached an agreement in October 2011 ... to Capsalus Corp (OTCBB:WELL.OB, or "Capsalus"). Capsalus assumed management of ...
... Laboratory has entered into a contractual agreement for ancillary ... Network and their 8.6 million lives network. ... pioneer of claims optimization, Stratose (formerly operating as Coalition ... KeyClaims) works to reduce the cost and ensure the ...
Cached Biology Technology:Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 2Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 3GeneLink Reports 2011 Financial Results 2GeneLink Reports 2011 Financial Results 3Aviir Laboratories Announce National Agreement with Stratose 2Aviir Laboratories Announce National Agreement with Stratose 3
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Saudi Arabia Biomedical Sensors Market - Growth, ... The Saudi Arabia Biomedical Sensors market ... CAGR of 3.64% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... Duke University Medical Center and Laboratory Corporation of ... formation of a joint venture to commercialize new ... the translation of newly discovered biomarkers into widely ... responses, predict disease progression, and evaluate any number ...
... NASA,s Aqua and Terra satellites fly around the ... land changes. Over the last three days these satellites ... plume from the Eyjafjallajkull volcano in Iceland. Eyjafjallajkull ... spewing ash into the atmosphere. Volcanic eruptions are important ...
... 2010 Scientists from The Scripps Research Institute have provided ... mutations lead to Type 1 diabetes. This new molecular understanding ... other autoimmune diseases. The study was published in an ... on April 19, 2010, and will appear in the ...
Cached Biology News:Duke, LabCorp combine forces to create the Biomarker Factory 22 NASA Satellites Capture Last 3 Days of Eyjafjallajokull's Ash Plume 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 3
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... 20 Plasma Immunodepletion Kit specifically removes 20 ... plasma or serum in preparation for further ... into the plasma proteome whether you use ... chromatography or go straight to mass spectrometry. ...
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
Biology Products: